Reviewer's report
Title:Safety and efficacy of the immunosuppressive agent 6-tioguanine in
murine model of acute colitis
Version: 1Date:19 October 2010
Reviewer: Danyvid Olivares-Villagomez
Reviewer's report:
The paper entitled “Safety and efficacy of the immunosuppressive agent
6-tioguanine in murine model of acute colitis” by Kverka et al, asks whether
6-tioguanine (6-TG) is a safe compound to use for the treatment of acute colitis,
comparing it to other compounds, such as, azathioprine (AZA). The authors used
the well-established model of colitis induced by administration of DSS in the
drinking water. Their results indicated that treatment with 6-TG reduces the level
of colitis severity in comparison to mice treated with AZA.
Major compulsory revisions:
1. As shown in their results, AZA treatment does not ameliorate colitis in this
model. However, AZA is used to treat patients with IBD. The authors should
clarify why in their system AZA does not ameliorate disease in comparison to
PBS-treated mice.
Minor essential revisions:
None
Discretionary revisions:
1. Although the author’s used a model for acute colitis, and therefore, short
exposure to the drugs, it will be important to determine the toxicity of 6-TG in a
chronic model of colitis (which can be accomplished using various cycles of DSS)
or by increasing the amounts of 6-TG (may be 60 micrograms).
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare I have no competing interests.
Reviewer's report
Title:Safety and efficacy of the immunosuppressive agent 6-tioguanine in
murine model of acute colitis
Version: 1Date:19 October 2010
Reviewer: Danyvid Olivares-Villagomez
Reviewer's report:
The paper entitled “Safety and efficacy of the immunosuppressive agent
6-tioguanine in murine model of acute colitis” by Kverka et al, asks whether
6-tioguanine (6-TG) is a safe compound to use for the treatment of acute colitis,
comparing it to other compounds, such as, azathioprine (AZA). The authors used
the well-established model of colitis induced by administration of DSS in the
drinking water. Their results indicated that treatment with 6-TG reduces the level
of colitis severity in comparison to mice treated with AZA.
Major compulsory revisions:
1. As shown in their results, AZA treatment does not ameliorate colitis in this
model. However, AZA is used to treat patients with IBD. The authors should
clarify why in their system AZA does not ameliorate disease in comparison to
PBS-treated mice.
Minor essential revisions:
None
Discretionary revisions:
1. Although the author’s used a model for acute colitis, and therefore, short
exposure to the drugs, it will be important to determine the toxicity of 6-TG in a
chronic model of colitis (which can be accomplished using various cycles of DSS)
or by increasing the amounts of 6-TG (may be 60 micrograms).
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare I have no competing interests.
Please review this paper.
user
Reviewer's report
Title:Safety and efficacy of the immunosuppressive agent 6-tioguanine in
murine model of acute colitis
Version: 1Date:19 October 2010
Reviewer: Danyvid Olivares-Villagomez
Reviewer's report:
The paper entitled “Safety and efficacy of the immunosuppressive agent
6-tioguanine in murine model of acute colitis” by Kverka et al, asks whether
6-tioguanine (6-TG) is a safe compound to use for the treatment of acute colitis,
comparing it to other compounds, such as, azathioprine (AZA). The authors used
the well-established model of colitis induced by administration of DSS in the
drinking water. Their results indicated that treatment with 6-TG reduces the level
of colitis severity in comparison to mice treated with AZA.
Major compulsory revisions:
1. As shown in their results, AZA treatment does not ameliorate colitis in this
model. However, AZA is used to treat patients with IBD. The authors should
clarify why in their system AZA does not ameliorate disease in comparison to
PBS-treated mice.
Minor essential revisions:
None
Discretionary revisions:
1. Although the author’s used a model for acute colitis, and therefore, short
exposure to the drugs, it will be important to determine the toxicity of 6-TG in a
chronic model of colitis (which can be accomplished using various cycles of DSS)
or by increasing the amounts of 6-TG (may be 60 micrograms).
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare I have no competing interests.
assistant